title: [Treatment of atopic dermatitis: practical approach].
abstract: Atopic dermatitis (AD) is a chronic disease frequent in childhood. The treatment is based on regular moisturizing of the skin, information to the parents on the chronic course with recurrent flares, topical anti-infectious therapy for superinfections and colonization of the skin by staphylococcus aureus, and topical steroids. The immuno-modulatory macrolides (tacrolimus and pimecrolimus) represent a new alternative to topical steroids. These molecules are well tolerated, but theirs effects on the long-term are unknown. A food allergy may be responsible for a AD flare in up to a third of the cases, but the presence of an allergy should be demonstrated before the prescription of an elimination diet. AD is often the first manifestation of atopy: the physician should be aware of the future occurence of respiratory symptoms.
authors.affiliation: dr.rossetti@bluewin.ch
authors.forename: G
authors.initials: G
authors.lastname: Rossetti
authors.forename: E
authors.initials: E
authors.lastname: Laffitte
authors.forename: P A
authors.initials: PA
authors.lastname: Eigenmann
authors.forename: J
authors.initials: J
authors.lastname: Lübbe
authors.forename: D
authors.initials: D
authors.lastname: Hohl
authors.forename: M F
authors.initials: MF
authors.lastname: Hofer
mesh_terms: D000305:Adrenal Cortex Hormones / Q000627:therapeutic use; D003876:Dermatitis, Atopic / Q000175:diagnosis / Q000209:etiology / Q000628:therapy*; D004643:Emollients / Q000627:therapeutic use; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D010290:Parents / Q000523:psychology; D010349:Patient Compliance; D011379:Prognosis
chemical_list: D000305:Adrenal Cortex Hormones; D004643:Emollients; D007166:Immunosuppressive Agents